CRISPR Therapeutics AG (NASDAQ: CRSP) kicked off on Tuesday, down -1.55% from the previous trading day, before settling in for the closing price of $53.95. Over the past 52 weeks, CRSP has traded in a range of $37.55-$91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 33402.13%. While this was happening, its average annual earnings per share was recorded -186.49%. With a float of $81.12 million, this company’s outstanding shares have now reached $84.92 million.
The extent of productivity of a business whose workforce counts for 407 workers is very important to gauge.
CRISPR Therapeutics AG (CRSP) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.47%, while institutional ownership is 66.52%. The most recent insider transaction that took place on Jun 21 ’24, was worth 188,799. In this transaction Chief Operating Officer of this company sold 3,366 shares at a rate of $56.09, taking the stock ownership to the 6,745 shares. Before that another transaction happened on Apr 15 ’24, when Company’s Chief Executive Officer sold 19,582 for $59.91, making the entire transaction worth $1,173,232. This insider now owns 208,122 shares in total.
CRISPR Therapeutics AG (CRSP) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -186.49% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Take a look at CRISPR Therapeutics AG’s (CRSP) current performance indicators. Last quarter, stock had a quick ratio of 17.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.72, a number that is poised to hit -1.43 in the next quarter and is forecasted to reach -4.49 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
The latest stats from [CRISPR Therapeutics AG, CRSP] show that its last 5-days average volume of 1.19 million was inferior to 1.64 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 7.28%. Additionally, its Average True Range was 2.64.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 5.23%, which indicates a significant increase from 3.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.46% in the past 14 days, which was lower than the 48.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.55, while its 200-day Moving Average is $60.55. Now, the first resistance to watch is $53.89. This is followed by the second major resistance level at $54.67. The third major resistance level sits at $55.35. If the price goes on to break the first support level at $52.43, it is likely to go to the next support level at $51.75. Assuming the price breaks the second support level, the third support level stands at $50.97.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
The company with the Market Capitalisation of 4.51 billion has total of 84,918K Shares Outstanding. Its annual sales at the moment are 371,210 K in contrast with the sum of -153,610 K annual income. Company’s last quarter sales were recorded 500 K and last quarter income was -116,590 K.
